Suppr超能文献

在磷脂酶C存在的情况下载脂蛋白A-I与卵磷脂-胆固醇囊泡的相互作用

Interaction of apolipoprotein A-I with lecithin-cholesterol vesicles in the presence of phospholipase C.

作者信息

Gudheti Manasa V, Gonzalez Yamaira I, Lee Sum P, Wrenn Steven P

机构信息

Department of Chemical Engineering, College of Engineering, Drexel University, Philadelphia, PA 19104, USA.

出版信息

Biochim Biophys Acta. 2003 Dec 30;1635(2-3):127-41. doi: 10.1016/j.bbalip.2003.11.003.

Abstract

Here we study the anti-nucleating mechanism of apolipoprotein A-I (apo A-I) on model biliary vesicles in the presence of phospholipase C (PLC) utilizing dynamic light scattering (DLS), steady-state fluorescence spectroscopy, cryogenic transmission electron microscopy (cryo-TEM), and UV/Vis spectroscopy. PLC induces aggregation of cholesterol-free lecithin vesicles from an initial, average size of 100 nm to a maximal size of 600 nm. The presence of apo A-I likely inhibits vesicle aggregation by shielding the PLC-generated hydrophobic moieties, which results in vesicles of an average size of 200 nm. A similar phenomenon is observed in cholesterol-enriched lecithin vesicles. Whereas PLC alone produces aggregates of 300 nm, no aggregation is observed when apo A-I is present along with PLC. However, the ability of apo A-I to inhibit aggregation is temporary, and after 8 h, a broad particle size distribution with sizes as high as 800 nm is observed. Apo A-I possibly induces the formation of small apo A-I/lecithin/cholesterol complexes of about 5-20 nm similar to the discoidal pre-HDL complexes found in blood when it can no longer effectively shield all the DAG molecules. Concomitant with formation of complexes, DAG molecules coalesce into large oil droplets, which account for the large particles observed by light scattering. Thus, apo A-I acts as an anti-nucleating agent by two mechanisms, anti-aggregation and microstructural transition. The mode of protection is dependent on the cholesterol content and the relative amounts of DAG and apo A-I present. This study supports the possibility of apo A-I solubilizing lipids in bile in a similar fashion as it does in blood and also delineates the mechanism of formation of the complexes.

摘要

在此,我们利用动态光散射(DLS)、稳态荧光光谱、低温透射电子显微镜(cryo-TEM)和紫外/可见光谱,研究了载脂蛋白A-I(apo A-I)在磷脂酶C(PLC)存在下对模型胆汁囊泡的抗成核机制。PLC可诱导无胆固醇卵磷脂囊泡从初始平均大小100 nm聚集至最大大小600 nm。apo A-I的存在可能通过屏蔽PLC产生的疏水部分来抑制囊泡聚集,从而产生平均大小为200 nm的囊泡。在富含胆固醇的卵磷脂囊泡中也观察到类似现象。单独的PLC会产生300 nm的聚集体,而当apo A-I与PLC同时存在时则未观察到聚集现象。然而,apo A-I抑制聚集的能力是暂时的,8小时后,观察到粒径分布范围很宽,最大粒径高达800 nm。当apo A-I不能再有效屏蔽所有二酰甘油(DAG)分子时,它可能会诱导形成约5 - 20 nm的小apo A-I/卵磷脂/胆固醇复合物,类似于血液中发现的盘状前高密度脂蛋白(pre-HDL)复合物。伴随着复合物的形成,DAG分子聚集成大油滴,这就是光散射观察到的大颗粒的原因。因此,apo A-I通过抗聚集和微观结构转变两种机制作为抗成核剂发挥作用。保护模式取决于胆固醇含量以及DAG和apo A-I的相对含量。这项研究支持了apo A-I在胆汁中以与在血液中类似的方式溶解脂质的可能性,并且还阐明了复合物的形成机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验